151 related articles for article (PubMed ID: 26260387)
21. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells.
Papa V; Tazzari PL; Chiarini F; Cappellini A; Ricci F; Billi AM; Evangelisti C; Ottaviani E; Martinelli G; Testoni N; McCubrey JA; Martelli AM
Leukemia; 2008 Jan; 22(1):147-60. PubMed ID: 17928881
[TBL] [Abstract][Full Text] [Related]
22. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
Nishioka C; Ikezoe T; Yang J; Takeuchi S; Koeffler HP; Yokoyama A
Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
[TBL] [Abstract][Full Text] [Related]
23. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
Bali P; George P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Scuto A; Annavarapu S; Fiskus W; Moscinski L; Atadja P; Bhalla K
Clin Cancer Res; 2004 Aug; 10(15):4991-7. PubMed ID: 15297399
[TBL] [Abstract][Full Text] [Related]
24. Novel indoloquinoline derivative, IQDMA, inhibits STAT5 signaling associated with apoptosis in K562 cells.
Yang SH; Chien CM; Su JC; Chen YL; Chang LS; Lin SR
J Biochem Mol Toxicol; 2008; 22(6):396-404. PubMed ID: 19111001
[TBL] [Abstract][Full Text] [Related]
25. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
George P; Bali P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Fiskus W; Scuto A; Annavarapu S; Moscinski L; Bhalla K
Cancer Res; 2004 May; 64(10):3645-52. PubMed ID: 15150124
[TBL] [Abstract][Full Text] [Related]
26. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts.
Tazzari PL; Cappellini A; Ricci F; Evangelisti C; Papa V; Grafone T; Martinelli G; Conte R; Cocco L; McCubrey JA; Martelli AM
Leukemia; 2007 Mar; 21(3):427-38. PubMed ID: 17215852
[TBL] [Abstract][Full Text] [Related]
27. Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT).
Ozawa Y; Williams AH; Estes ML; Matsushita N; Boschelli F; Jove R; List AF
Leuk Res; 2008 Jun; 32(6):893-903. PubMed ID: 18179820
[TBL] [Abstract][Full Text] [Related]
28. Tetraspanin CD82 drives acute myeloid leukemia chemoresistance by modulating protein kinase C alpha and β1 integrin activation.
Floren M; Restrepo Cruz S; Termini CM; Marjon KD; Lidke KA; Gillette JM
Oncogene; 2020 May; 39(19):3910-3925. PubMed ID: 32203165
[TBL] [Abstract][Full Text] [Related]
29. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Yang J; Koeffler HP; Yokoyama A
Leukemia; 2008 Dec; 22(12):2159-68. PubMed ID: 18784743
[TBL] [Abstract][Full Text] [Related]
30. Activation of triggering receptor expressed on myeloid cells-1 protects monocyte from apoptosis through regulation of myeloid cell leukemia-1.
Cai M; Chen Q; Chen C; Liu X; Hou J; Zeng C; Shu Q; Fang X
Anesthesiology; 2013 May; 118(5):1140-9. PubMed ID: 23364598
[TBL] [Abstract][Full Text] [Related]
31. Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors.
Talieri M; Diamandis EP; Katsaros N; Gourgiotis D; Scorilas A
Thromb Haemost; 2003 Jun; 89(6):1081-8. PubMed ID: 12783122
[TBL] [Abstract][Full Text] [Related]
32. Histone acetyltransferase 1 up regulates Bcl2L12 expression in nasopharyngeal cancer cells.
Miao BP; Zhang RS; Yang G; Sun JJ; Tang YY; Liang WF; Liu T; Wen Z; Yang PC; Nie GH
Arch Biochem Biophys; 2018 May; 646():72-79. PubMed ID: 29621521
[TBL] [Abstract][Full Text] [Related]
33. Quantitative expression analysis of the apoptosis-related gene, BCL2L12, in head and neck squamous cell carcinoma.
Geomela PA; Kontos CK; Yiotakis I; Scorilas A
J Oral Pathol Med; 2013 Feb; 42(2):154-61. PubMed ID: 22747515
[TBL] [Abstract][Full Text] [Related]
34. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells.
Mohammadi S; Ghaffari SH; Shaiegan M; Zarif MN; Nikbakht M; Akbari Birgani S; Alimoghadam K; Ghavamzadeh A
Life Sci; 2016 May; 152():190-8. PubMed ID: 27063991
[TBL] [Abstract][Full Text] [Related]
35. Tetraspanin CD82 Regulates the Spatiotemporal Dynamics of PKCα in Acute Myeloid Leukemia.
Termini CM; Lidke KA; Gillette JM
Sci Rep; 2016 Jul; 6():29859. PubMed ID: 27417454
[TBL] [Abstract][Full Text] [Related]
36. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
[TBL] [Abstract][Full Text] [Related]
37. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
[TBL] [Abstract][Full Text] [Related]
38. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
[TBL] [Abstract][Full Text] [Related]
39. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.
Rahmani M; Reese E; Dai Y; Bauer C; Kramer LB; Huang M; Jove R; Dent P; Grant S
Mol Pharmacol; 2005 Apr; 67(4):1166-76. PubMed ID: 15625278
[TBL] [Abstract][Full Text] [Related]
40. Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma.
Stegh AH; DePinho RA
Cell Cycle; 2011 Jan; 10(1):33-8. PubMed ID: 21200141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
